Sign In
Buy ICCM
$2.89
+0 (+0%)
At Close: Jul 31, 2026
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
08:25am, Wednesday, 29'th Jul 2026
The petition by The Society of Interventional Oncology (SIO) includes adding criteria for patients aged 50-69 who are poor surgical candidates or who decline surgery in the National Comprehensive Canc
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
08:32am, Monday, 27'th Jul 2026
Company signed agreement with the West Cancer Center & Research Institute, the first clinical site for its post-marketing study for ProSense® cryoablation in the treatment of low-risk breast cancer C
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
08:32am, Tuesday, 14'th Jul 2026
CAESAREA, Israel, July 14, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
08:11am, Monday, 06'th Jul 2026
Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization Independent study evaluating breast cance
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:12am, Thursday, 25'th Jun 2026
CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that dest
Published in the International Journal of Surgery, globally ranked in the top three among surgery journals , the article highlights strong clinical outcomes with ProSense® cryoablation and describe
CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro
IceCure Stock Surges After 70% ProSense Install Increase
12:45pm, Wednesday, 17'th Jun 2026
IceCure Medical Ltd. (NASDAQ:ICCM) shares are soaring Wednesday after the company reported a 70% jump in its U.S. commercial install base for ProSense, its breast cancer cryoablation system.
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
08:25am, Wednesday, 17'th Jun 2026
Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences c
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
08:30am, Tuesday, 02'nd Jun 2026
Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (the "Company" or "IceCure" or
At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
04:30pm, Wednesday, 13'th May 2026
No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares CAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or t
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
12:40pm, Tuesday, 12'th May 2026
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates
10:41am, Tuesday, 12'th May 2026
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03.
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America
08:30am, Tuesday, 12'th May 2026
Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearance Acc
